Hormonal
Use of GLP-1 receptor agonists (GLP1-RAs) is not associated with an increased risk of thyroid cancer compared to DPP-4 inhibitors in patients with type 2 diabetes.
If you have type 2 diabetes and are considering a GLP-1 medication like Ozempic or Wegovy, current large-scale evidence suggests it does not increase your risk of thyroid cancer compared to other common diabetes drugs. While rodent studies showed thyroid effects, this has not been observed in human population studies.
Overall, use of GLP1-RA relative to use of DPP-4i was not associated with an increased risk of thyroid cancer (pooled weighted HR 0.81, 95% CI 0.59-1.12).
Why this rating
Large multisite cohort study with robust active comparator design, though follow-up is relatively short (1.8-3.0 years).
Source
Glucagon-Like Peptide 1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study
Sarah A. Baxter et al. · Thyroid · 2025
DOI 10.1089/thy.2024.0387
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →